<?xml version="1.0" ?>
<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2024//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_240101.dtd">
<PubmedArticleSet>
<PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Automated"><PMID Version="1">36142282</PMID><DateCompleted><Year>2022</Year><Month>09</Month><Day>26</Day></DateCompleted><DateRevised><Year>2022</Year><Month>12</Month><Day>07</Day></DateRevised><Article PubModel="Electronic"><Journal><ISSN IssnType="Electronic">1422-0067</ISSN><JournalIssue CitedMedium="Internet"><Volume>23</Volume><Issue>18</Issue><PubDate><Year>2022</Year><Month>Sep</Month><Day>08</Day></PubDate></JournalIssue><Title>International journal of molecular sciences</Title><ISOAbbreviation>Int J Mol Sci</ISOAbbreviation></Journal><ArticleTitle>Venous Thromboembolic Disease in COVID-19, Pathophysiology, Therapy and Prophylaxis.</ArticleTitle><ELocationID EIdType="pii" ValidYN="Y">10372</ELocationID><ELocationID EIdType="doi" ValidYN="Y">10.3390/ijms231810372</ELocationID><Abstract><AbstractText>For over two years, the world has been facing the epidemiological and health challenge of the coronavirus disease 2019 (COVID-19) pandemic, caused by the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection. Growing problems are also complications after the development of COVID-19 in the form of post and long- COVID syndromes, posing a challenge for the medical community, both for clinicians and the scientific world. SARS-CoV-2 infection is associated with an increased risk of cardiovascular complications, especially thromboembolic complications, which are associated with both thrombosis of small and very small vessels due to immunothrombosis, and the development of venous thromboembolism. Low molecular wight heparin (LMHW) are the basic agents used in the prevention and treatment of thromboembolic complications in COVID-19. There is still a great deal of controversy regarding both the prevention and treatment of thromboembolic complications, including the prophylaxis dose or the optimal duration of anticoagulant treatment in patients with an episode of venous thromboembolism.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Dybowska</LastName><ForeName>Ma&#x142;gorzata</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Department of Lung Diseases, National Tuberculosis and Lung Diseases Research Institute, 01-138 Warsaw, Poland.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Wyrostkiewicz</LastName><ForeName>Dorota</ForeName><Initials>D</Initials><AffiliationInfo><Affiliation>Department of Lung Diseases, National Tuberculosis and Lung Diseases Research Institute, 01-138 Warsaw, Poland.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Opoka</LastName><ForeName>Lucyna</ForeName><Initials>L</Initials><AffiliationInfo><Affiliation>Department of Radiology, National Tuberculosis and Lung Diseases Research Institute, 01-138 Warsaw, Poland.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Lewandowska</LastName><ForeName>Katarzyna</ForeName><Initials>K</Initials><Identifier Source="ORCID">0000-0002-4648-2864</Identifier><AffiliationInfo><Affiliation>Department of Lung Diseases, National Tuberculosis and Lung Diseases Research Institute, 01-138 Warsaw, Poland.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Sobiecka</LastName><ForeName>Ma&#x142;gorzata</ForeName><Initials>M</Initials><Identifier Source="ORCID">0000-0001-9311-9753</Identifier><AffiliationInfo><Affiliation>Department of Lung Diseases, National Tuberculosis and Lung Diseases Research Institute, 01-138 Warsaw, Poland.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Tomkowski</LastName><ForeName>Witold</ForeName><Initials>W</Initials><AffiliationInfo><Affiliation>Department of Lung Diseases, National Tuberculosis and Lung Diseases Research Institute, 01-138 Warsaw, Poland.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Szturmowicz</LastName><ForeName>Monika</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Department of Lung Diseases, National Tuberculosis and Lung Diseases Research Institute, 01-138 Warsaw, Poland.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D016454">Review</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2022</Year><Month>09</Month><Day>08</Day></ArticleDate></Article><MedlineJournalInfo><Country>Switzerland</Country><MedlineTA>Int J Mol Sci</MedlineTA><NlmUniqueID>101092791</NlmUniqueID><ISSNLinking>1422-0067</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D000925">Anticoagulants</NameOfSubstance></Chemical><Chemical><RegistryNumber>9005-49-6</RegistryNumber><NameOfSubstance UI="D006493">Heparin</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000925" MajorTopicYN="N">Anticoagulants</DescriptorName><QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000086382" MajorTopicYN="Y">COVID-19</DescriptorName><QualifierName UI="Q000150" MajorTopicYN="N">complications</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D006493" MajorTopicYN="N">Heparin</DescriptorName><QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000086402" MajorTopicYN="N">SARS-CoV-2</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D054556" MajorTopicYN="Y">Venous Thromboembolism</DescriptorName><QualifierName UI="Q000188" MajorTopicYN="N">drug therapy</QualifierName><QualifierName UI="Q000209" MajorTopicYN="N">etiology</QualifierName><QualifierName UI="Q000517" MajorTopicYN="N">prevention &amp; control</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D020246" MajorTopicYN="Y">Venous Thrombosis</DescriptorName><QualifierName UI="Q000188" MajorTopicYN="N">drug therapy</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000094024" MajorTopicYN="N">Post-Acute COVID-19 Syndrome</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000093485" MajorTopicYN="Y">COVID-19 Drug Treatment</DescriptorName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">COVID-19</Keyword><Keyword MajorTopicYN="N">NETs</Keyword><Keyword MajorTopicYN="N">SARS-CoV-2</Keyword><Keyword MajorTopicYN="N">anticoagulation treatment</Keyword><Keyword MajorTopicYN="N">immunothrombosis</Keyword><Keyword MajorTopicYN="N">thromboprophylaxis</Keyword><Keyword MajorTopicYN="N">venous thromboembolism</Keyword></KeywordList><CoiStatement>The authors declare no conflict of interest.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2022</Year><Month>8</Month><Day>3</Day></PubMedPubDate><PubMedPubDate PubStatus="revised"><Year>2022</Year><Month>9</Month><Day>5</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2022</Year><Month>9</Month><Day>6</Day></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2022</Year><Month>9</Month><Day>23</Day><Hour>1</Hour><Minute>22</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2022</Year><Month>9</Month><Day>24</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2022</Year><Month>9</Month><Day>28</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2022</Year><Month>9</Month><Day>8</Day></PubMedPubDate></History><PublicationStatus>epublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">36142282</ArticleId><ArticleId IdType="pmc">PMC9499629</ArticleId><ArticleId IdType="doi">10.3390/ijms231810372</ArticleId><ArticleId IdType="pii">ijms231810372</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>World Health Organization  Novel Coronavirus (2019-nCoV). Situation Report.  [(accessed on 1 August 2022)]; Available online:  https://www.who.int/emergencies/diseases/novel-coronavirus-2019.</Citation></Reference><Reference><Citation>Guan W.J., Ni Z.Y., Hu Y., Liang W.H., Ou C.Q., He J.X., Liu L., Shan H., Lei C.L., Hui D.S.C., et al. China Medical Treatment Expert Group for COVID-19. Clinical Characteristics of Coronavirus Disease 2019 in China. N. Engl. J. Med. 2020;382:1708&#x2013;1720. doi: 10.1056/NEJMoa2002032.</Citation><ArticleIdList><ArticleId IdType="doi">10.1056/NEJMoa2002032</ArticleId><ArticleId IdType="pmc">PMC7092819</ArticleId><ArticleId IdType="pubmed">32109013</ArticleId></ArticleIdList></Reference><Reference><Citation>Jim&#xe9;nez D., Garc&#xed;a-Sanchez A., Rali P., Muriel A., Bikdeli B., Ruiz-Artacho P., Le Mao R., Rodr&#xed;guez C., Hunt B.J., Monreal M. Incidence of VTE and Bleeding among Hospitalized Patients with Coronavirus Disease 2019: A Systematic Review and Meta-analysis. Chest. 2021;159:1182&#x2013;1196. doi: 10.1016/j.chest.2020.11.005.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.chest.2020.11.005</ArticleId><ArticleId IdType="pmc">PMC7670889</ArticleId><ArticleId IdType="pubmed">33217420</ArticleId></ArticleIdList></Reference><Reference><Citation>Nopp S., Moik F., Jilma B., Pabinger I., Ay C. Risk of venous thromboembolism in patients with COVID-19: A systematic review and meta-analysis. Res. Pract. Thromb. Haemost. 2020;4:1178&#x2013;1191. doi: 10.1002/rth2.12439.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/rth2.12439</ArticleId><ArticleId IdType="pmc">PMC7537137</ArticleId><ArticleId IdType="pubmed">33043231</ArticleId></ArticleIdList></Reference><Reference><Citation>Zuin M., Engelen M.M., Bilato C., Vanassche T., Rigatelli G., Verhamme P., Vandenbriele C., Zuliani G., Roncon L. Prevalence of Acute Pulmonary Embolism at Autopsy in Patients with COVID-19. Am. J. Cardiol. 2022;171:59&#x2013;164. doi: 10.1016/j.amjcard.2022.01.051.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.amjcard.2022.01.051</ArticleId><ArticleId IdType="pmc">PMC8902912</ArticleId><ArticleId IdType="pubmed">35277253</ArticleId></ArticleIdList></Reference><Reference><Citation>Jackson C.B., Farzan M., Chen B., Choe H. Mechanisms of SARS-CoV-2 entry into cells. Nat. Rev. Mol. Cell Biol. 2022;23:3&#x2013;20. doi: 10.1038/s41580-021-00418-x.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41580-021-00418-x</ArticleId><ArticleId IdType="pmc">PMC8491763</ArticleId><ArticleId IdType="pubmed">34611326</ArticleId></ArticleIdList></Reference><Reference><Citation>Engelmann B., Massberg S. Thrombosis as an intravascular effector of innate immunity. Nat. Rev. Immunol. 2013;13:34&#x2013;45. doi: 10.1038/nri3345.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/nri3345</ArticleId><ArticleId IdType="pubmed">23222502</ArticleId></ArticleIdList></Reference><Reference><Citation>Gould T.J., Vu T.T., Swystun L.L., Dwivedi D.J., Mai S.H., Weitz J.I., Liaw P.C. Neutrophil extracellular traps promote thrombin generation through platelet-dependent and platelet-independent mechanisms. Arterioscler. Thromb. Vasc. Biol. 2014;34:1977&#x2013;1984. doi: 10.1161/ATVBAHA.114.304114.</Citation><ArticleIdList><ArticleId IdType="doi">10.1161/ATVBAHA.114.304114</ArticleId><ArticleId IdType="pubmed">25012129</ArticleId></ArticleIdList></Reference><Reference><Citation>Kimball A.S., Obi A.T., Diaz J.A., Henke P.K. The Emerging Role of NETs in Venous Thrombosis and Immunothrombosis. Front. Immunol. 2016;7:236. doi: 10.3389/fimmu.2016.00236.</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fimmu.2016.00236</ArticleId><ArticleId IdType="pmc">PMC4921471</ArticleId><ArticleId IdType="pubmed">27446071</ArticleId></ArticleIdList></Reference><Reference><Citation>Agier J., Efenberger M., Brzezi&#x144;ska-B&#x142;aszczyk E. Cathelicidin impact on inflammatory cells. Central Eur. J. Immunol. 2015;40:225&#x2013;235. doi: 10.5114/ceji.2015.51359.</Citation><ArticleIdList><ArticleId IdType="doi">10.5114/ceji.2015.51359</ArticleId><ArticleId IdType="pmc">PMC4637384</ArticleId><ArticleId IdType="pubmed">26557038</ArticleId></ArticleIdList></Reference><Reference><Citation>Loo J., Spittle D.A., Newnham M. COVID-19, immunothrombosis and venous thromboembolism: Biological mechanisms. Thorax. 2021;76:412&#x2013;420. doi: 10.1136/thoraxjnl-2020-216243.</Citation><ArticleIdList><ArticleId IdType="doi">10.1136/thoraxjnl-2020-216243</ArticleId><ArticleId IdType="pubmed">33408195</ArticleId></ArticleIdList></Reference><Reference><Citation>Montazersaheb S., Hosseiniyan Khatibi S.M., Hejazi M.S., Tarhriz V., Farjami A., Ghasemian Sorbeni F., Farahzadi R., Ghasemnejad T. COVID-19 infection: An overview on cytokine storm and related interventions. Virol. J. 2022;19:92. doi: 10.1186/s12985-022-01814-1.</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/s12985-022-01814-1</ArticleId><ArticleId IdType="pmc">PMC9134144</ArticleId><ArticleId IdType="pubmed">35619180</ArticleId></ArticleIdList></Reference><Reference><Citation>Szturmowicz M., Demkow U. Neutrophil Extracellular Traps (NETs) in severe SARS-CoV-2 lung disease. Int. J. Mol. Sci. 2021;22:8854. doi: 10.3390/ijms22168854.</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/ijms22168854</ArticleId><ArticleId IdType="pmc">PMC8396177</ArticleId><ArticleId IdType="pubmed">34445556</ArticleId></ArticleIdList></Reference><Reference><Citation>Pearson J.D. Endothelial cell function and thrombosis. Clin. Haematol. 1999;12:329&#x2013;341. doi: 10.1053/beha.1999.0028.</Citation><ArticleIdList><ArticleId IdType="doi">10.1053/beha.1999.0028</ArticleId><ArticleId IdType="pubmed">10856973</ArticleId></ArticleIdList></Reference><Reference><Citation>Zuo Y., Zuo M., Yalavarthi S., Gockman K., Madison J.A., Shi H., Woodard W., Lezak S.P., Lugogo N.L., Knight J.S., et al. Neutrophil extracellular traps and thrombosis in COVID-19. J. Thromb. Thrombolysis. 2021;51:446&#x2013;453. doi: 10.1007/s11239-020-02324-z.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s11239-020-02324-z</ArticleId><ArticleId IdType="pmc">PMC7642240</ArticleId><ArticleId IdType="pubmed">33151461</ArticleId></ArticleIdList></Reference><Reference><Citation>Jim&#xe9;nez-Alc&#xe1;zar M., Napirei M., Panda R., K&#xf6;hler E.C., Kremer Hovinga J.A., Mannherz H.G., Peine S., Renn&#xe9; T., Lmmle B., Fuchs T.A. Impaired DNase1-mediated degradation of neutrophil extracellular traps is associated with acute thrombotic microangiopathies. J. Thromb. Haemost. 2015;13:732&#x2013;742. doi: 10.1111/jth.12796.</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/jth.12796</ArticleId><ArticleId IdType="pubmed">25418346</ArticleId></ArticleIdList></Reference><Reference><Citation>Bonaventura A., Vecchi&#xe9; A., Dagna L., Martinod K., Dixon D.L., Van Tassell B.W., Dentali F., Montecucco F., Massberg S., Levi M., et al. Endothelial dysfunction and immunothrombosis as key pathogenic mechanisms in COVID-19. Nat. Rev. Immunol. 2021;21:319&#x2013;329. doi: 10.1038/s41577-021-00536-9.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41577-021-00536-9</ArticleId><ArticleId IdType="pmc">PMC8023349</ArticleId><ArticleId IdType="pubmed">33824483</ArticleId></ArticleIdList></Reference><Reference><Citation>Whyte C.S., Morrow G.B., Mitchell J.L., Chowdary P., Mutch N.J. Fibrinolytic abnormalities in acute respiratory distress syndrome (ARDS) and versatility of thrombolytic drugs to treat COVID-19. J. Thromb. Haemost. 2020;18:1548&#x2013;1555. doi: 10.1111/jth.14872.</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/jth.14872</ArticleId><ArticleId IdType="pmc">PMC7264738</ArticleId><ArticleId IdType="pubmed">32329246</ArticleId></ArticleIdList></Reference><Reference><Citation>Massberg S., Grahl L., von Bruehl M.L., Manukyan D., Pfeiler S., Goosmann C., Brinkmann V., Lorenz M., Bidzhekov K., Khandagale A.B. Reciprocal coupling of coagulation and innate immunity via neutrophil serine proteases. Nat. Med. 2010;16:887&#x2013;896. doi: 10.1038/nm.2184.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/nm.2184</ArticleId><ArticleId IdType="pubmed">20676107</ArticleId></ArticleIdList></Reference><Reference><Citation>Acherjee T., Behara A., Saad M., Vittorio T.J. Mechanisms and management of prothrombotic state in COVID-19 disease. Ther. Adv. Cardiovasc. Dis. 2021;15:1&#x2013;13. doi: 10.1177/17539447211053470.</Citation><ArticleIdList><ArticleId IdType="doi">10.1177/17539447211053470</ArticleId><ArticleId IdType="pmc">PMC8785300</ArticleId><ArticleId IdType="pubmed">34693818</ArticleId></ArticleIdList></Reference><Reference><Citation>Panigada M., Bottino N., Tagliabue P., Grasselli G., Novembrino C., Chantarangkul V., Pesenti A., Peyvandi F., Tripodi A. Hypercoagulability of COVID-19 patients in intensive care unit: A report of thromboelastography findings and other parameters of hemostasis. J. Thromb. Haemost. 2020;18:1738&#x2013;1742. doi: 10.1111/jth.14850.</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/jth.14850</ArticleId><ArticleId IdType="pmc">PMC9906150</ArticleId><ArticleId IdType="pubmed">32302438</ArticleId></ArticleIdList></Reference><Reference><Citation>Tang N., Li D., Wang X., Sun Z. Abnormal coagulation parameters are associated with poor prognosis in patients with novel coronavirus pneumonia. J. Thromb. Haemost. 2020;18:844&#x2013;847. doi: 10.1111/jth.14768.</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/jth.14768</ArticleId><ArticleId IdType="pmc">PMC7166509</ArticleId><ArticleId IdType="pubmed">32073213</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhou F., Yu T., Du R., Fan G., Liu Y., Liu Z., Xiang J., Wang Y., Song B., Gu X., et al. Clinical course and risk factors for mortality of adult inpatients with COVID-19 in Wuhan, China: A retrospective cohort study. Lancet. 2020;395:1054&#x2013;1062. doi: 10.1016/S0140-6736(20)30566-3.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S0140-6736(20)30566-3</ArticleId><ArticleId IdType="pmc">PMC7270627</ArticleId><ArticleId IdType="pubmed">32171076</ArticleId></ArticleIdList></Reference><Reference><Citation>Artifoni M., Danic G., Gautier G., Gicquel P., Boutoille D., Raffi F., N&#xe9;el A., Lecomte R. Systematic assessment of venous thromboembolism in COVID-19 patients receiving thromboprophylaxis: Incidence and role of D-dimer as predictive factors. J. Thromb. Thrombolysis. 2020;50:211&#x2013;216. doi: 10.1007/s11239-020-02146-z.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s11239-020-02146-z</ArticleId><ArticleId IdType="pmc">PMC7246965</ArticleId><ArticleId IdType="pubmed">32451823</ArticleId></ArticleIdList></Reference><Reference><Citation>Leentjens J., van Haaps T.F., Wessels P.F., Schutgens R.E.G., Middeldorp S. COVID-19-associated coagulopathy and antithrombotic agents-lessons after 1 year. Lancet Haematol. 2021;8:e524&#x2013;e533. doi: 10.1016/S2352-3026(21)00105-8.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S2352-3026(21)00105-8</ArticleId><ArticleId IdType="pmc">PMC8078884</ArticleId><ArticleId IdType="pubmed">33930350</ArticleId></ArticleIdList></Reference><Reference><Citation>Ackermann M., Verleden S.E., Kuehnel M., Haverich A., Welte T., Laenger F., Vanstapel A., Werlein C., Stark H., Tzankov A., et al. Pulmonary Vascular Endothelialitis, Thrombosis, and Angiogenesis in COVID-19. N. Engl. J. Med. 2020;383:120&#x2013;128. doi: 10.1056/NEJMoa2015432.</Citation><ArticleIdList><ArticleId IdType="doi">10.1056/NEJMoa2015432</ArticleId><ArticleId IdType="pmc">PMC7412750</ArticleId><ArticleId IdType="pubmed">32437596</ArticleId></ArticleIdList></Reference><Reference><Citation>Lopes R.D., de Barros E., Silva P.G.M., Furtado R.H.M., Macedo A.V.S., Bronhara B., Damiani L.P., Barbosa L.M., de Aveiro Morata J., Ramacciotti E., et al. ACTION Coalition COVID-19 Brazil IV Investigators. Therapeutic versus prophylactic anticoagulation for patients admitted to hospital with COVID-19 and elevated D-dimer concentration (ACTION): An open-label, multicentre, randomised, controlled trial. Lancet. 2021;397:2253&#x2013;2263. doi: 10.1016/S0140-6736(21)01203-4.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S0140-6736(21)01203-4</ArticleId><ArticleId IdType="pmc">PMC8177770</ArticleId><ArticleId IdType="pubmed">34097856</ArticleId></ArticleIdList></Reference><Reference><Citation>Clausen T.M., Sandoval D.R., Spliid C.B., Pihl J., Perrett H.R., Painter C.D., Narayanan A., Majowicz S.A., Kwong E.M., McVicar R.N., et al. SARS-CoV-2 Infection Depends on Cellular Heparan Sulfate and ACE2. Cell. 2020;183:1043&#x2013;1057.e15. doi: 10.1016/j.cell.2020.09.033.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.cell.2020.09.033</ArticleId><ArticleId IdType="pmc">PMC7489987</ArticleId><ArticleId IdType="pubmed">32970989</ArticleId></ArticleIdList></Reference><Reference><Citation>Buijsers B., Yanginlar C., Maciej-Hulme M.L., de Mast Q., van der Vlag J. Beneficial non-anticoagulant mechanisms underlying heparin treatment of COVID-19 patients. eBioMedicine. 2020;59:102969. doi: 10.1016/j.ebiom.2020.102969.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.ebiom.2020.102969</ArticleId><ArticleId IdType="pmc">PMC7445140</ArticleId><ArticleId IdType="pubmed">32853989</ArticleId></ArticleIdList></Reference><Reference><Citation>National Institutes of Health  COVID-19 Treatment Guidelines Panel. Coronavirus Disease 2019 (COVID-19) Treatment Guidelines. National Institutes of Health.  [(accessed on 31 May 2022)]; Available online:  https://www.covid19treatmentguidelines.nih.gov/</Citation></Reference><Reference><Citation>Cuker A., Tseng E.K., Nieuwlaat R., Angchaisuksiri P., Blair C., Dane K., DeSancho M.T., Diuguid D.L., Griffin D.O., Kahn S.R., et al. American Society of Hematology living guidelines on the use of anticoagulation for thromboprophylaxis in patients with COVID-19: January 2022 update on the use of therapeutic-intensity anticoagulation in acutely ill patients. Blood Adv. 2022;6:4915&#x2013;4923. doi: 10.1182/bloodadvances.2022007561.</Citation><ArticleIdList><ArticleId IdType="doi">10.1182/bloodadvances.2022007561</ArticleId><ArticleId IdType="pmc">PMC9068240</ArticleId><ArticleId IdType="pubmed">35503027</ArticleId></ArticleIdList></Reference><Reference><Citation>Schulman S., Sholzberg M., Spyropoulos A.C., Zarychanski R., Resnick H.E., Bradbury C., Broxmeyer L., Connors J.M., Falanga A., Iba T., et al. ISTH guidelines for antithrombotic treatment in COVID-19. J. Thromb. Haemost. 2022. early view .</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/jth.15808</ArticleId><ArticleId IdType="pmc">PMC9349907</ArticleId><ArticleId IdType="pubmed">35906716</ArticleId></ArticleIdList></Reference><Reference><Citation>Kollias A., Kyriakoulis K.G., Trontzas I.P., Rapti V., Kyriakoulis I.G., Theochari C.A., Dimakakos E., Poulakou G., Syrigos K. High versus Standard Intensity of Thromboprophylaxis in Hospitalized Patients with COVID-19: A Systematic Review and Meta-Analysis. J. Clin. Med. 2021;10:5549. doi: 10.3390/jcm10235549.</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/jcm10235549</ArticleId><ArticleId IdType="pmc">PMC8658422</ArticleId><ArticleId IdType="pubmed">34884258</ArticleId></ArticleIdList></Reference><Reference><Citation>ATTACC Investigators. ACTIV-4a Investigators. REMAP-CAP Investigators. Lawler P.R., Goligher E.C., Berger J.S., Neal M.D. Therapeutic Anticoagulation with Heparin in Noncritically Ill Patients with COVID-19. N. Engl. J. Med. 2021;385:790&#x2013;802.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8362594</ArticleId><ArticleId IdType="pubmed">34351721</ArticleId></ArticleIdList></Reference><Reference><Citation>Sholzberg M., Tang G.H., Rahhal H., AlHamzah M., Kreuziger L.B., &#xc1;inle F.N., Alomran F., Alayed K., Alsheef M., AlSumait F., et al. RAPID trial investigators. Effectiveness of therapeutic heparin versus prophylactic heparin on death, mechanical ventilation, or intensive care unit admission in moderately ill patients with COVID-19 admitted to hospital: RAPID randomised clinical trial. BMJ. 2021;375:2400. doi: 10.1136/bmj.n2400.</Citation><ArticleIdList><ArticleId IdType="doi">10.1136/bmj.n2400</ArticleId><ArticleId IdType="pmc">PMC8515466</ArticleId><ArticleId IdType="pubmed">34649864</ArticleId></ArticleIdList></Reference><Reference><Citation>Spyropoulos A.C., Goldin M., Giannis D., Diab W., Wang J., Khanijo S., Mignatti A., Gianos E., Cohen M., Sharifova G., et al. HEP-COVID Investigators. Efficacy and Safety of Therapeutic-Dose Heparin vs. Standard Prophylactic or Intermediate-Dose Heparins for Thromboprophylaxis in High-risk Hospitalized Patients with COVID-19: The HEP-COVID Randomized Clinical Trial. JAMA Intern. Med. 2021;181:1612&#x2013;1620. doi: 10.1001/jamainternmed.2021.6203.</Citation><ArticleIdList><ArticleId IdType="doi">10.1001/jamainternmed.2021.6203</ArticleId><ArticleId IdType="pmc">PMC8498934</ArticleId><ArticleId IdType="pubmed">34617959</ArticleId></ArticleIdList></Reference><Reference><Citation>REMAP-CAP Investigators. ACTIV-4a Investigators. ATTACC Investigators. Goligher E.C., Bradbury C.A., McVerry B.J., Lawler P.R., Berger J.S., Gong M.N., Carrier M., et al. Therapeutic Anticoagulation with Heparin in Critically Ill Patients with COVID-19. N. Engl. J. Med. 2021;385:777&#x2013;789.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8362592</ArticleId><ArticleId IdType="pubmed">34351722</ArticleId></ArticleIdList></Reference><Reference><Citation>Cuker A., Tseng E.K., Nieuwlaat R., Angchaisuksiri P., Blair C., Dane K., Davila J., DeSancho M.T., Diuguid D., Griffin D.O., et al. American Society of Hematology living guidelines on the use of anticoagulation for thromboprophylaxis in patients with COVID-19: July 2021 update on postdischarge thromboprophylaxis. Blood Adv. 2022;6:664&#x2013;671. doi: 10.1182/bloodadvances.2021005945.</Citation><ArticleIdList><ArticleId IdType="doi">10.1182/bloodadvances.2021005945</ArticleId><ArticleId IdType="pmc">PMC8566097</ArticleId><ArticleId IdType="pubmed">34727173</ArticleId></ArticleIdList></Reference><Reference><Citation>Gonzalez-Ochoa A.J., Raffetto J.D., Hern&#xe1;ndez A.G., Zavala N., Guti&#xe9;rrez O., Vargas A., Loustaunau J. Sulodexide in the Treatment of Patients with Early Stages of COVID-19: A Randomized Controlled Trial. Thromb. Haemost. 2021;121:944&#x2013;954. doi: 10.1055/a-1414-5216.</Citation><ArticleIdList><ArticleId IdType="doi">10.1055/a-1414-5216</ArticleId><ArticleId IdType="pubmed">33677827</ArticleId></ArticleIdList></Reference><Reference><Citation>Lopes R.D., de Barros E., Silva P.G.M., Furtado R.H.M., Macedo A.V.S., Ramacciotti E., Damini L.P., Bronhara B., Cavalcanti A.B., Rosa R.G., et al. Randomized clinical trial to evaluate a routine full anticoagulation Strategy in Patients with Coronavirus Infection (SARS-CoV2) admitted to hospital: Rationale and design of the ACTION (AntiCoagulaTlon cOroNavirus)-Coalition IV trial. Am. Heart J. 2021;238:1&#x2013;11. doi: 10.1016/j.ahj.2021.04.005.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.ahj.2021.04.005</ArticleId><ArticleId IdType="pmc">PMC8057688</ArticleId><ArticleId IdType="pubmed">33891907</ArticleId></ArticleIdList></Reference><Reference><Citation>Wang C., Yu C., Jing H., Wu X., Novakovic V.A., Xie R., Shi J. Long COVID: The Nature of Thrombotic Sequelae Determines the Necessity of Early Anticoagulation. Front. Cell Infect. Microbiol. 2022;12:861703. doi: 10.3389/fcimb.2022.861703.</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fcimb.2022.861703</ArticleId><ArticleId IdType="pmc">PMC9016198</ArticleId><ArticleId IdType="pubmed">35449732</ArticleId></ArticleIdList></Reference><Reference><Citation>Ramacciotti E., Agati L.B., Calderaro D., Volpiani G.G., de Oliveira C.C.C., Aguiar V.C.R., Rodrigues E., Sobreira M.L., Joviliano E.E., Dusilek C., et al. Medically Ill hospitalized Patients for COVID-19 THrombosis Extended ProphyLaxis with rivaroxaban ThErapy: Rationale and Design of the MICHELLE Trial. Am. Heart J. 2021;242:115&#x2013;122. doi: 10.1016/j.ahj.2021.08.016.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.ahj.2021.08.016</ArticleId><ArticleId IdType="pmc">PMC8409017</ArticleId><ArticleId IdType="pubmed">34480880</ArticleId></ArticleIdList></Reference><Reference><Citation>Mutua V., Gershwin L.J. A Review of Neutrophil Extracellular Traps (NETs) in Disease: Potential Anti-NETs Therapeutics. Clin. Rev. Allergy Immunol. 2021;61:194&#x2013;211. doi: 10.1007/s12016-020-08804-7.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s12016-020-08804-7</ArticleId><ArticleId IdType="pmc">PMC7395212</ArticleId><ArticleId IdType="pubmed">32740860</ArticleId></ArticleIdList></Reference><Reference><Citation>RECOVERY Collaborative Group Aspirin in patients admitted to hospital with COVID-19 (RECOVERY): A randomised, controlled, open-label, platform trial. Lancet. 2021;399:143&#x2013;151.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8598213</ArticleId><ArticleId IdType="pubmed">34800427</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle></PubmedArticleSet>